You are here

Coronavirus (COVID-19): Information on medicines and medical devices

The TGA is publishing the latest information about medicines and medical devices as it relates to COVID-19 on this page.

Please read the information below before contacting the TGA to see if your question is already answered.

Filters
22 January 2022

On 18 January 2022 the TGA granted provisional approval to Pfizer Australia Pty Ltd’s oral COVID-19 treatment nirmatrelvir + ritonavir (PAXLOVID).

22 January 2022

On 18 January 2022 the TGA granted provisional approval to Merck Sharp & Dohme (Australia) Pty Ltd for its oral COVID-19 treatment, LAGEVRIO (molnupiravir).

21 January 2022

A list of self-tests that are approved in Australia

21 January 2022
A list of tests approved for inclusion in the Australian Register of Therapeutic Goods (ARTG)
21 January 2022

The TGA has granted provisional approval to Biocelect Pty Ltd (on behalf of Novavax Inc) for its COVID-19 vaccine, NUVAXOVID.

20 January 2022
On 19 January 2022 the TGA granted provisional approval to Biocelect Pty Ltd (on behalf of Novavax Inc) in relation to the COVID-19 vaccine, NVX-CoV2373, for individuals aged 18 years and over.
20 January 2022

COVID-19 vaccines undergoing evaluation for provisional registration by the TGA

20 January 2022

COVID-19 treatments that have received a provisional determination from the TGA

20 January 2022

COVID-19 treatments that have been provisionally approved for use in Australia

20 January 2022

COVID-19 treatments undergoing evaluation for provisional registration by the TGA

Pages

Further information

Contact TGA Info

Tel: 1800 020 653
Email: info@tga.gov.au

Note: we are currently experiencing a high volume of calls and emails. Please bear with us as we try to respond to queries as quickly as possible.

Department of Health

Coronavirus (COVID-19) health alert — for information and advice not specific to therapeutic goods.

Follow us